Sugi Predict

Sugi Predict / Compounds / SCHEMBL15948455

SCHEMBL15948455

SCHEMBL15948455

C=CC(=O)N1CCN(C(C)=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ KDM4E B2RXH2 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ PIK3CD O00329 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.41
▸ KMT2A Q03164 5/20 0.41
▸ TET3 O43151 4/20 0.41
▸ FBXL19 Q6PCT2 4/20 0.41
▸ CXXC5 Q7LFL8 4/20 0.41
▸ KDM2B Q8NHM5 4/20 0.41
▸ CXXC4 Q9H2H0 4/20 0.41
▸ KDM2A Q9Y2K7 4/20 0.41
▸ TET1 Q8NFU7 3/20 0.41
▸ CASP6 P55212 1/20 0.38
▸ GFER P55789 1/20 0.38
▸ HPGD P15428 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ ITGB2 P05107 1/20 0.36
▸ ICAM1 P05362 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29070247 0.88 SMN1; SMN2 (0.67) CYP1A2TDP1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL20547259 0.87 TET3 (0.47) ALDH1A1KMT2ATET3FBXL19CXXC5
SCHEMBL12764449 0.87 TET3 (0.47) ALDH1A1KMT2ATET3FBXL19CXXC5
SCHEMBL167151 0.87 TET3 (0.47) ALDH1A1KMT2ATET3FBXL19CXXC5
SCHEMBL237862 0.87 — —
SCHEMBL21393050 0.83 LMNA (0.47) CYP1A2TDP1SMN1; SMN2ALDH1A1HPGD
SCHEMBL792365 0.83 CYP1A2 (0.41) CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD
SCHEMBL860793 0.81 CYP1A2 (0.77) CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD
SCHEMBL14407779 0.81 CYP1A2 (0.77) CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD
SCHEMBL37407 0.81 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113164495-B Covalent targeting of E3 ligases 加利福尼亚大学董事会 2025-04-22 — — CN disclosed
US-20250120982-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-04-17 — — US disclosed
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2025-01-09 — — US disclosed
US-12161648-B2 Covalent targeting of E3 ligases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 — — US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 — — US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 — — US disclosed
EP-3863642-A1 COVALENT TARGETING OF E3 LIGASES The Regents of the University of California (US) 2021-08-18 — — EP disclosed
CN-113164495-A Covalent targeting of E3 ligase 加利福尼亚大学董事会 2021-07-23 — — CN disclosed
EP-2953457-B1 ERK INHIBITORS AND USES THEREOF CELGENE CAR LLC (BM) 2020-04-08 — — EP disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 — — US disclosed
US-9796700-B2 ERK inhibitors and uses thereof CELGENE CAR LLC (BM) 2017-10-24 — — US disclosed
US-20170210729-A1 ERK INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2017-07-27 — — US disclosed
US-20170137406-A1 ERK INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2017-05-18 — — US disclosed
US-9561228-B2 ERK inhibitors and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2017-02-07 — — US disclosed
US-9504686-B2 ERK inhibitors and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2016-11-29 — — US disclosed
US-20160082008-A1 ERK INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2016-03-24 — — US disclosed
US-20160002176-A1 ERK INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2016-01-07 — — US disclosed
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2015-12-31 — — US disclosed
US-9145387-B2 ERK inhibitors and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2015-09-29 — — US disclosed
US-20140228322-A1 ERK INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-08-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137406-A1 ERK INHIBITORS AND USES THEREOF MAP3K20, MAP3K1, MAPK3 CYP1A2 3896/4885TDP1 2390/4885KDM4E 1412/4885
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, DUSP2, MKNK1 CYP1A2 1428/4885TDP1 3334/4885KDM4E 1468/4885
US-20160002176-A1 ERK INHIBITORS AND USES THEREOF MAPK1, MAPK3, MAP4K2 CYP1A2 3993/4885TDP1 2480/4885KDM4E 3344/4885
US-12161648-B2 Covalent targeting of E3 ligases RNF114, RNF4, RNF168 CYP1A2 3732/4885TDP1 1403/4885KDM4E 210/4885
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 CYP1A2 4418/4885TDP1 2216/4885KDM4E 3016/4885
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF KEAP1, NFE2L2, NQO1 CYP1A2 2686/4885TDP1 4107/4885KDM4E 2252/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 CYP1A2 3732/4885TDP1 1403/4885KDM4E 210/4885
US-20170210729-A1 ERK INHIBITORS AND USES THEREOF MAP3K20, MAP3K1, MAPK3 CYP1A2 3896/4885TDP1 2390/4885KDM4E 1412/4885
US-20160082008-A1 ERK INHIBITORS AND USES THEREOF MAP3K20, MAP3K1, MAPK3 CYP1A2 3896/4885TDP1 2390/4885KDM4E 1412/4885
US-20250120982-A1 COVALENT TARGETING OF E3 LIGASES STUB1, XIAP, RBX1 CYP1A2 4400/4885TDP1 1234/4885KDM4E 1093/4885
US-20140228322-A1 ERK INHIBITORS AND USES THEREOF MAP3K20, MAP3K1, MAPK3 CYP1A2 3896/4885TDP1 2390/4885KDM4E 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.